Patents Represented by Attorney, Agent or Law Firm Steve T. Zelson, Esq.
  • Patent number: 6268343
    Abstract: The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: July 31, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Liselotte Bjerre Knudsen, Per Olaf Huusfeldt, Per Franklin Nielsen, Niels C. Kaarsholm, Helle Birk Olsen, Søren Erik Bjørn, Freddy Zimmerdahl Pedersen, Kjeld Madsen
  • Patent number: 6262044
    Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: July 17, 2001
    Assignees: Novo Nordisk A/S, Ontogen Corporation
    Inventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
  • Patent number: 6248090
    Abstract: A syringe having a dose setting mechanism, a button which can be operated to inject a set dose, a switch operated at a time between the start and completion of injection, and an electronic presentation of parameters such as the size of a set dose and the size of the last dose administered. The syringe also has a stop watch which is reset and started responsive to operation of the switch. The electronic presentation includes an indication of the number of hours elapsed from the activation of the switch, and may also include, for a predetermined period initially following the activation of the switch, a presentation of the number of seconds elapsed. The latter presentation can provide a visual indication to the patient of the length of time, after the injection button has been actuated to inject the dose, that the needle should remain inserted in the skin.
    Type: Grant
    Filed: August 20, 1998
    Date of Patent: June 19, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Jens Moller Jensen, Jens Ulrik Poulsen, Jorgen K. Smedegaard
  • Patent number: 6242443
    Abstract: 1,2,4-Benzothiadiazine derivatives represented by formula wherein D, R1, R2, R3, R4, R5, R12, R13, R14, R15 are defined in the description, composition thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.
    Type: Grant
    Filed: June 17, 1997
    Date of Patent: June 5, 2001
    Assignee: Novo Nordisk AIS
    Inventors: Bernard Pirotte, Philippe Lebrun, Pascal De Tullio, Fabian Somers, Jacques Delarge, John Bondo Hansen, Flemming Elmelund Nielsen, Holger Claus Hansen, John Patrick Mogensen, Tina Møller-Tagmose
  • Patent number: 6239148
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: May 29, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Florenzio Zaragossa Dörwald, Knud Erik Andersen, Rolf Hohlweg, Peter Madsen, Tine Krogh Jørgensen, Uffe Bang Olsen, Henrik Sune Andersen, Svend Treppendahl, Polivka Zdenék, Silhánková Alexandra, Sindelár Karel
  • Patent number: 6239163
    Abstract: A new salt of (2R,3R,4R)-3,4-dihydroxy-2-hyroxymethylpyrrolidine is disclosed. Specifically, (2R,3R,4R-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 2-naphthalenesulfonate is disclosed, as well as its preparation and use for treating and preventing diabetes and obesity and for regulating appetite. This salt is characterized as having a high melting point and low hygroscopicity.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: May 29, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Claus Ulrich Jessen, Petra Christine Lugstein
  • Patent number: 6238878
    Abstract: The invention relates to compounds inhibiting the activation of FX to FXa by TF/FVIIa. The compounds are anticoagulants. The invention also relates to a method of identifying a drug candidate.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: May 29, 2001
    Assignee: Novo Norkisk AIS
    Inventors: Palle Jakobsen, Egon Persson
  • Patent number: 6235004
    Abstract: The present invention provides an injection syringe comprises a housing including a holder for containing a cartridge of medicine, a piston rod with a non-circular cross-section having an outer thread, a piston rod drive, a one way coupling having an annular ring of internal ratchet notches, which annular ring can be integral with the housing, and a pawl having at least a pair of resilient arms each having a free end.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: May 22, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Søren Steenfeldt-Jensen, Steffen Hansen
  • Patent number: 6232310
    Abstract: The present invention relates to fused 1,4-thiazine-2-carbonitrile derivatives, compositions thereof and methods for preparing the compounds. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: May 15, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Holger Claus Hansen, Tina Møller Tagmose, John Bondo Hansen
  • Patent number: 6231540
    Abstract: An injection member for a jet spray injection device through which device a dose of medicine is administered for subcutaneous or intramuscular injection has a jet nozzle designed as a skin-penetrating member having a length of 0.05-0.3 mm enabling it just to penetrate the stratum corneum.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: May 15, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Jørgen K. Smedegaard
  • Patent number: 6225310
    Abstract: 1,2,4-Thiadiazine and 1,4-thiazine derivates represented by formula (I): wherein A, B, D, R1, R2, R3 and R4 are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: May 1, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Flemming Elmelund Nielsen, John Bondo Hansen, Holger Claus Hansen, Tina Møller Tagmose, John Patrick Mogensen
  • Patent number: 6225329
    Abstract: The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like, wherein A, R1, R2, R3, R4, R16 and R17 are as defined in the specification.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: May 1, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Lutz Stefan Richter, Henrik Sune Andersen, Josef Vagner, Claus Bekker Jeppesen, Niels Peter Hundahl Møller, Sven Branner, Jing Su, Farid Bakir, Luke Milburn Judge
  • Patent number: 6214816
    Abstract: The compounds are N-substituted azaheterocyclic compounds of formula I wherein R1 and R2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, C1-6-alkyl or C1-6-alkoxy; and Y is >N—CH2— wherein only the underscored atom participates in the ring system; and X is —C(R6R7)—, —CH2CH2—, —CH═CH—CH2—, —CH2—CH═CH—, —CH2—(C═O)—, —(C═O)—CH2—, —CH2CH2CH2—, —CH═CH—, CH(R10)CH2—, —CH2CH(R10) or —(C═O)— wherein R6 and R7 independently are hydrogen or C1-6-alkyl and wherein R10 is C1-6-alkyl or phenyl; and r is 0, 1 or 2; and Z is selected from wherein A is —CH2—, —O—, —S— or —N(R5)— wherein R5 is H or C1-6-alkyl; and R3 is —(CH2)pCOR4 wherein p is 1, 2, 3 or 4 and R4 is OH, NH2, NHOH or C1-6-alkoxy; or a pharmaceutically acceptable salt th
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: April 10, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Rolf Hohlweg, Tine Krogh Jørgensen, Knud Erik Andersen, Uffe Bang Olsen, Zdenék Polivka, Karel Sindelar
  • Patent number: 6214820
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: April 10, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Patent number: 6211144
    Abstract: Concentrated aqueous insulin formulations of high physical and chemical stability are disclosed. The formulations are highly suitable for pulmonary delivery.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: April 3, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Svend Havelund
  • Patent number: 6207682
    Abstract: Modified release formulations with zero-order drug release containing (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid, or a pharmaceutically acceptable salt thereof, dispersed in a polymeric matrix having at least one release rate controlling polymer are useful in treating disorders related to both neurogenic inflammation and non-insulin-dependent diabetes mellitus (NIDDM).
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: March 27, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Tina Meinertz Andersen, Thyge Borup Hjorth, Kim Westi Jorgensen
  • Patent number: 6197352
    Abstract: The staling of leavened baked products such as bread is retarded by adding an enzyme with exoamylase activity to the flour or dough used for producing the baked product in question.
    Type: Grant
    Filed: January 30, 1992
    Date of Patent: March 6, 2001
    Assignees: Novo Nordisk A/S, Novo Alle
    Inventor: Tine Olesen
  • Patent number: 6197567
    Abstract: Enzymes produced by mutating the genes for a number of subtilisin proteases and expressing the mutated genes in suitable hosts are presented. The enzyme exhibit improved wash performance in comparison to their wild type parent enzymes. The enzymes are well-suited for use in detergent compositions.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: March 6, 2001
    Assignees: Novo Nordisk A/S, Unilever PLC
    Inventors: Dorrit Aaslyng, Sven Branner, Sven Hastrup, Leif Nørskov-Lauritsen, Ole Hvilsted Olsen, Merete Simonsen, Eric Casteleijn, Maarten Robert Egmond, Johan Haverkamp, John David Marugg, Arnoldus Theodorus Anthonius Mooren
  • Patent number: 6190883
    Abstract: The invention describes industrial fermentation of a Saccharomyces yeast species for production of a heterologous product encoded by a plasmid or DNA contained in said Saccharomyces yeast species which method utilizes the substrate more efficiently and without fermentative metabolism resulting in formation of ethanol and other unwanted primary products of fermentative activity whereby high yields of the heterologous product are obtained. The Saccharomyces yeast species is preferably a Crabtree negative Saccharomyces species in particular Saccharomyces kluyveri.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: February 20, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Aradhana Srivastava, Jure Piskur, Jens Nielsen, Michi Egel-Mitani
  • Patent number: D444226
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: June 26, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Anders Geert-Jensen, Mikal Christian Jørgensen